Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | FDPS | P14324 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253010 | 0.84 | HCAR2 (0.52) | MAPK14LCKRAB9ANPC1FDPS | |
| SCHEMBL12715552 | 0.84 | RAB9A (0.54) | MAPK14CCNE1CDK2CDK5LCK | |
| SCHEMBL19710761 | 0.83 | MAPK14 (0.57) | MAPK14CDK2LCKRAB9ANPC1 | |
| SCHEMBL12715554 | 0.74 | ALDH1A1 (0.53) | MAPK14LCKRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14213429 | 0.74 | MAPK14 (0.61) | MAPK14CCNE1CDK2CDK5LCK | |
| SCHEMBL18997957 | 0.74 | HCAR2 (0.62) | CCNE1CDK2CDK5RAB9ASMN1; SMN2 | |
| SCHEMBL12715605 | 0.73 | MAPK14 (0.47) | MAPK14CCNE1CDK2LCKSMN1; SMN2 | |
| SCHEMBL27395757 | 0.73 | ALDH1A1 (0.38) | MAPK14CCNE1CDK2CDK5RAB9A | |
| SCHEMBL15087979 | 0.72 | HCAR2 (0.50) | MAPK14CCNE1CDK2CDK5LCK | |
| SCHEMBL21481994 | 0.71 | SMN1; SMN2 (0.74) | MAPK14RAB9ANPC1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783573-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783573-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-10 | — | — | US | disclosed |
| US-20150322111-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322111-A1 | IAP ANTAGONISTS | XIAP, BIRC5, API5 | MAPK14 2211/4885CCNE1 863/4885CDK2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.